Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 134, Issue 12, Pages 2947-2956Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2014.258
Keywords
-
Categories
Funding
- Ente Cassa di Risparmio di Firenze (ECRF)
- Fondazione Farmacogenomica FiorGen
- Associazione Italiana Ricerca Cancro (AIRC)
- Regione Toscana
- Istituto Toscano Tumori (ITT)
- Fondazione Umberto Veronesi
Ask authors/readers for more resources
The CD63 tetraspanin is highly expressed in the early stages of melanoma and decreases in advanced lesions, suggesting it as a possible suppressor of tumor progression. We employed loss- and gain-of-gene-function approaches to investigate the role of CD63 in melanoma progression and acquisition of the epithelial-to-mesenchymal transition (EMT) program. We used two human melanoma cell lines derived from primary tumors and one primary human melanoma cell line isolated from a cutaneous metastasis, differing by levels of CD63 expression. CD63-silenced melanoma cells showed enhanced motility and invasiveness with downregulation of E-cadherin and upregulation of N-cadherin and Snail. In parallel experiments, transient and stable ectopic expression of CD63 resulted in a robust reduction of cell motility, invasiveness, and protease activities, which was proportional to the increase in CD63 protein level. Transfected cells overexpressing the highest level of CD63 when transplanted into immunodeficient mice showed a reduced incidence and rate of tumor growth. Moreover, these cells showed a reduction of N-cadherin, Vimentin, Zeb1, and a-SMA, and a significant resistance to undergo an EMT program both in basal condition and in the following stimulation with TGF beta. Thus, our results establish a previously unreported mechanistic link between the tetraspanin CD63 and EMT abrogation in melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available